Ethics of a partially effective dengue vaccine: Lessons from the Philippines

Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had prior dengue virus (DENV) infections but sensitized seronegative children to brea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Vaccine
Hlavní autoři: Halstead, Scott B., Katzelnick, Leah C., Russell, Philip K., Markoff, Lewis, Aguiar, Maira, Dans, Leonila R., Dans, Antonio L.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier Ltd. 2020
Témata:
Commentary
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7347470/
https://ncbi.nlm.nih.gov/pubmed/32654899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2020.06.079
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky